Next Article in Journal
Development and Application of a Label-Free Fluorescence Method for Determining the Composition of Gold Nanoparticle–Protein Conjugates
Next Article in Special Issue
Mechanisms and Αpplications of Ιnterleukins in Cancer Immunotherapy
Previous Article in Journal
Responses to Oxidative and Heavy Metal Stresses in Cyanobacteria: Recent Advances
Previous Article in Special Issue
Low-Dose Interleukin-2 Therapy: A Driver of an Imbalance between Immune Tolerance and Autoimmunity
Open AccessReview

Cytokine-Modulating Strategies and Newer Cytokine Targets for Arthritis Therapy

Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore Street, HSF-1, Suite 380, Baltimore, MD 21201, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Bing Yan
Int. J. Mol. Sci. 2015, 16(1), 887-906; https://doi.org/10.3390/ijms16010887
Received: 10 November 2014 / Accepted: 25 December 2014 / Published: 31 December 2014
(This article belongs to the Special Issue Mechanism of Action and Applications of Cytokines in Immunotherapy)
Cytokines are the key mediators of inflammation in the course of autoimmune arthritis and other immune-mediated diseases. Uncontrolled production of the pro-inflammatory cytokines such as interferon-γ (IFN-γ), tumor necrosis factor α (TNFα), interleukin-6 (IL-6), and IL-17 can promote autoimmune pathology, whereas anti-inflammatory cytokines including IL-4, IL-10, and IL-27 can help control inflammation and tissue damage. The pro-inflammatory cytokines are the prime targets of the strategies to control rheumatoid arthritis (RA). For example, the neutralization of TNFα, either by engineered anti-cytokine antibodies or by soluble cytokine receptors as decoys, has proven successful in the treatment of RA. The activity of pro-inflammatory cytokines can also be downregulated either by using specific siRNA to inhibit the expression of a particular cytokine or by using small molecule inhibitors of cytokine signaling. Furthermore, the use of anti-inflammatory cytokines or cytokine antagonists delivered via gene therapy has proven to be an effective approach to regulate autoimmunity. Unexpectedly, under certain conditions, TNFα, IFN-γ, and few other cytokines can display anti-inflammatory activities. Increasing awareness of this phenomenon might help develop appropriate regimens to harness or avoid this effect. Furthermore, the relatively newer cytokines such as IL-32, IL-34 and IL-35 are being investigated for their potential role in the pathogenesis and treatment of arthritis. View Full-Text
Keywords: autoimmunity; arthritis; biologics; cytokines; gene therapy; inflammation; interleukins; rheumatoid arthritis; siRNA autoimmunity; arthritis; biologics; cytokines; gene therapy; inflammation; interleukins; rheumatoid arthritis; siRNA
Show Figures

Figure 1

MDPI and ACS Style

Venkatesha, S.H.; Dudics, S.; Acharya, B.; Moudgil, K.D. Cytokine-Modulating Strategies and Newer Cytokine Targets for Arthritis Therapy. Int. J. Mol. Sci. 2015, 16, 887-906.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop